FAQ: Kairos Pharma's Presentation at H.C. Wainwright Global Investment Conference
Summary
What is the main announcement in this press release?
Kairos Pharma Ltd. announced that CEO and Chairman John Yu, MD will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York.
Where and when is the H.C. Wainwright conference taking place?
The conference is being held September 8-10, 2025 at the Lotte New York Palace Hotel in New York City.
What is Kairos Pharma’s focus and what is their lead candidate?
Kairos Pharma is a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics. Their lead candidate is ENV105, an antibody that targets CD105 to overcome drug resistance in cancer treatments.
How does ENV105 work and what cancer types is it targeting?
ENV105 targets CD105, a protein identified as a key driver of resistance to cancer treatments. It aims to reverse drug resistance and restore effectiveness of standard therapies, currently in Phase 2 trials for castrate-resistant prostate cancer and Phase 1 trials for lung cancer.
Where is Kairos Pharma based and what is their stock symbol?
Kairos Pharma is based in Los Angeles, California and trades on the NYSE American under the symbol KAPA.
Where can investors find more information about Kairos Pharma?
The latest news and updates relating to KAPA are available in the company’s newsroom at https://ibn.fm/KAPA. The full press release can be viewed at https://ibn.fm/mdybH.
What is the significance of this conference presentation for investors?
The presentation provides investors with a corporate overview directly from the CEO, offering insights into the company’s progress, clinical developments, and future prospects in cancer therapeutics.
What is the current clinical stage of ENV105 development?
ENV105 is currently in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer, addressing significant unmet medical needs in oncology.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 193439